Research programme: cancer and diabetes therapeutics - Evotec/SanofiAlternative Names: EVT 601; EVT 701; EVT 801; TargetBCD
Latest Information Update: 16 Aug 2016
At a glance
- Originator Evotec AG; Sanofi
- Class Cell therapies; Small molecules
- Mechanism of Action Pancreatic beta cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Research Diabetes mellitus